A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

about

Drug-induced liver injury in inflammatory bowel disease: 1-year prospective observational study

P2860

Q33805921-EC82FE4D-E975-4A09-978A-5D31BFBDF5F2

P2860

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

Item

http://www.wikidata.org/entity/Q40858310

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

2015年论文

@zh

2015年论文

@zh-cn

name

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

@en

type

Item

label

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

@en

prefLabel

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

@en

P1476

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

@en

P2093

Julian R F Walters

http://www.w3.org/2001/XMLSchema#string

Richard N Appleby

http://www.w3.org/2001/XMLSchema#string

P2860

Tissue-specific expression of betaKlotho and fibroblast growth factor (FGF) receptor isoforms determines metabolic activity of FGF19 and FGF21

FGF19 as a postprandial, insulin-independent activator of hepatic protein and glycogen synthesis

Endocrine fibroblast growth factors 15/19 and 21: from feast to famine

The role of bile after Roux-en-Y gastric bypass in promoting weight loss and improving glycaemic control

A mouse model of hepatocellular carcinoma: ectopic expression of fibroblast growth factor 19 in skeletal muscle of transgenic mice

Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial

Fibroblast growth factor 15 functions as an enterohepatic signal to regulate bile acid homeostasis

The human gallbladder secretes fibroblast growth factor 19 into bile: towards defining the role of fibroblast growth factor 19 in the enterobiliary tract.

Fibroblast growth factor 19 increases metabolic rate and reverses dietary and leptin-deficient diabetes.

Expression of fibroblast growth factor 19 is associated with recurrence and poor prognosis of hepatocellular carcinoma.

P304

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

editorial

P356

10.3978/J.ISSN.2305-5839.2015.03.38

http://www.w3.org/2001/XMLSchema#string

P433

Suppl 1

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Richard N Appleby

J R Walters

P577

2015-05-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

26046094

http://www.w3.org/2001/XMLSchema#string

P932

4437929

http://www.w3.org/2001/XMLSchema#string

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

about

P2860

P2860

A variant of FGF19 for treatment of disorders of cholestasis and bile acid metabolism

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932